Compare TransMedics Group Inc (TMDX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.19. The key difference: TransMedics Group Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| TMDX | YINN | |
|---|---|---|
Market Cap | $3.06B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $150.42 | $56.62 |
52-Week Low | $61.99 | $21.45 |
Enterprise Value | $3.46B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
YINN, the Direxion Daily FTSE China Bull 3x ETF, is trading at $28.05, down 7.49% with a bearish technical signal. The leveraged ETF faces pressure from mixed Chinese economic policies and U.S.-China trade tensions. Recent news highlights China's AI investment plans and export controls, creating volatility. Technical indicators show strong bearish momentum with moving averages signaling sell pressure.
The outlook remains cautious due to YINN's leveraged structure amplifying risks amid geopolitical uncertainty. While China's tech sector shows IPO momentum, the fund's inherent decay and China's economic stabilization efforts present both opportunity and significant risk for investors seeking Chinese equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
